- $7.38m
- $12.72m
- $0.05m
Brief: HCW Biologics Enters Crada With National Cancer Institute
Brief: HCW Biologics Granted Second Fundamental Patent
Brief: Masonic Cancer Center, University Of Minnesota To Present Phase 1 Clinical Trial Data For Hcw9218 In Solid Tumors
Brief: HCW Biologics Inc Reports Quarterly Net Loss Per Share Of $0.11
Brief: HCW Biologics Files For Mixed Shelf Of Up To $100 Million
Brief: HCW Biologics reports Q2 results
Brief: Hcw Biologics Inc Says Masonic Cancer Center Announced First Patient Was Dosed In Phase 1 Clinical Trial To Evaluate HCW9218
Brief: Hcw Biologics Reports First Quarter 2022 Financial Results And Recent Business Highlights
Brief: HCW Biologics Reports Fourth Quarter Results
Brief: Masonic Cancer Center At University Of Minnesota Receives FDA Clearance To Proceed With Phase 1 Clinical Trial In Solid Tumors For HCW9218
Brief: Hcw Biologics Inc. Announces Its Lead Product Candidate Shown To Augment Anti-Tumor Activity And Reduce Side Effects Of Chemotherapy Regimens
Brief: HCW Biologics Says Founder And CEO Named Weaver H. Gaines Entrepreneur Of The Year
Brief: HCW Biologics Reports Q3 Net Loss Of $4.1 Mln
Brief: HCW Biologics Shows Paper On Potential Of Cancer Immunotherapeutic
Brief: HCW Biologics Inc Estimates It Has Sufficient Cash To Fund Operations, Capex For At Least Next 24 Months
Brief: HCW Biologics Reports Second Quarter Financial Results
HCW Biologics IPO drops over 25%
NASDAQ RESUMED AT 10:48 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 04:01 AM